Comparative Pharmacology
Head-to-head clinical analysis: NADOLOL AND BENDROFLUMETHIAZIDE versus TRASICOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NADOLOL AND BENDROFLUMETHIAZIDE versus TRASICOR.
NADOLOL AND BENDROFLUMETHIAZIDE vs TRASICOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nadolol is a nonselective beta-adrenergic receptor antagonist that blocks beta1 and beta2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Bendroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water and reducing plasma volume.
Non-selective beta-adrenergic antagonist with intrinsic sympathomimetic activity (partial agonist) at beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure.
Nadolol 40–80 mg orally once daily; bendroflumethiazide 2.5–5 mg orally once daily. Dose titration based on blood pressure response.
20-40 mg orally three times daily, increased to 80-160 mg daily if needed; maximum 320 mg/day.
None Documented
None Documented
Nadolol: 14–24 h (mean 20 h); allows once-daily dosing. Bendroflumethiazide: 3–4 h (terminal); clinical duration longer due to prolonged action on distal tubule.
Terminal elimination half-life is approximately 8-12 hours in patients with normal renal function; may be prolonged in renal impairment, requiring dose adjustment.
Nadolol: ~70% renal unchanged, ≤5% fecal. Bendroflumethiazide: ~30% renal unchanged, ~70% renal as metabolites; minimal biliary.
Renal excretion of unchanged drug and metabolites accounts for approximately 80% of elimination, with about 20% appearing as unchanged drug; biliary/fecal excretion accounts for the remaining 20%.
Category C
Category C
Beta-Blocker
Beta-Blocker